REPAIRome specifically addresses the repair of one of the most serious types of DNA damage, DNA double-strand breaks (DSBs).

Katy Rezvani, MD, PhD, discusses advancements in CAR-NK cell therapy, focusing on enhancing antitumor efficacy while ensuring safety through precise gene editing techniques.

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the Unstoppable Stocks to Buy and Hold for the Next 5 Years. On September 23, ...

Becoming a millionaire through stock investing is possible, but it requires patience, discipline, and the acumen to make informed investment choices. Not every company can generate the kind of returns ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

A single one-time gene therapy could free patients with α-thalassemia, a rare and debilitating blood disorder, from the ...

One key finding is that deleting CDKN1B, a cell cycle regulator, increased CAR T cell proliferation and improved therapy persistence.

ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a ...